• Gilead Sciences and Kite are highlighting new late stage HIV and CAR T cell therapy data, along with regulatory updates, at upcoming medical meetings in 2026.
• Gilead Sciences plans to present Phase 3 results for a new single tablet HIV regimen and updates on HIV cure research at CROI 2026.
• Kite received an FDA label update for Yescarta that removes a key limitation of use in relapsed or refractory primary central nervous system lymphoma, expanding eligible patients for this CAR T cell therapy.

For investors watching NasdaqGS:GILD, these clinical and regulatory updates arrive with the stock at $154.98, supported by multi year returns, including 27.5% year to date and 51.4% over the past year. The 103.5% three year and 194.9% five year returns indicate that the market has already priced in meaningful expectations around Gilead Sciences HIV and oncology franchises.

Looking ahead, the upcoming CROI 2026 data and the broader Yescarta label provide fresh information to track how Gilead Sciences is shaping its HIV and cell therapy portfolios. The key questions will center on the durability and safety of the new HIV regimen, progress in cure research, and how the expanded Yescarta label translates into clinical adoption and real world use.

Stay updated on the most important news stories for Gilead Sciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Gilead Sciences.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$154.98, Gilead Sciences trades about 1.2% above the US$153.08 analyst target, sitting close to consensus.
• ✅ Simply Wall St Valuation: Simply Wall St’s model suggests the shares trade about 47.8% below estimated fair value, flagging a valuation gap.
• ✅ Recent Momentum: The 30 day return of 24.1% shows strong recent support as the HIV and CAR T cell updates land.

There is only one way to know the right time to buy, sell or hold Gilead Sciences. Head to Simply Wall St's company report for the latest analysis of Gilead Sciences's Fair Value.

Key Considerations

• 📊 The new HIV and CAR T cell data, plus the broader Yescarta label, feed directly into how durable Gilead Sciences HIV and oncology cash flows could be viewed.
• 📊 Watch CROI 2026 readouts, real world uptake under the updated Yescarta label, and how the current 22.6x P/E compares with Gilead Sciences earnings trajectory.
• ⚠️ One flagged risk is balance sheet leverage, so investors may want to see how any further R&D or commercialization spend interacts with existing debt.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Gilead Sciences analysis. Alternatively, you can check out the community page for Gilead Sciences to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.